Radiometals possess an exceptional breadth of decay properties and have been applied to
medicine with great success for several decades. The majority of current clinical use …

Background: Recent reports of the remarkable therapeutic efficacy of 225Ac-labeled PSMA-
617 for therapy of metastatic castration-resistant prostate cancer have underlined the clinical …

Background A remarkable therapeutic efficacy has been demonstrated with 225 Ac-prostate-
specific membrane antigen (PSMA)-617 in heavily pre-treated metastatic castration-resistant …

Among all existing radionuclides, only a few are of interest for therapeutic applications and
more specifically for targeted alpha therapy (TAT). From this selection, actinium-225 …

With a short particle range and high linear energy transfer, α-emitting radionuclides
demonstrate high cell-killing efficiencies. Even with the existence of numerous radionuclides …

Encouraging results from targeted α-therapy have received significant attention from
academia and industry. However, the limited availability of suitable radionuclides has …

Background: The development of radiopharmaceuticals containing 225Ac for targeted alpha
therapy is an active area of academic and commercial research worldwide. Objectives …

Alpha-emitters are radionuclides that decay through the emission of high linear energy
transfer α-particles and possess favorable pharmacologic profiles for cancer treatment …

Prostate cancer is the most commonly diagnosed malignancy in men and the second
leading cause of cancer-related deaths in Western civilization. Although localized prostate …

Recent clinical results have demonstrated remarkable treatment responses of late-stage
cancer patients when treated with alpha-emitting radionuclides such as actinium-225 …